Document Detail


Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.
MedLine Citation:
PMID:  16910165     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Many papers documented that Parkinson's disease (PD) patients treated with levodopa (L-dopa) shows elevated plasma homocysteine (Hcy) levels. Several lifestyle factors are able to influence plasma Hcy levels. We review the evidence that L-dopa therapy is related with an increase in plasma Hcy levels and that several behaviours could be able to cause changes in plasma Hcy concentrations. Therefore, there are reasons to suggest that a healthy lifestyle lowering Hcy may prevent this potential iatrogenic complication during L-dopa therapy. Moreover, at present, no controlled prospective studies have evaluated this phenomenon.
Authors:
Antonio Siniscalchi; Luca Gallelli; Nicola B Mercuri; Guido Ferreri Ibbadu; Giovambattista De Sarro
Related Documents :
18230915 - Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-s...
18437035 - Increased homocysteine levels in tear fluid of patients with primary open-angle glaucoma.
16983185 - Behavioural and psychological symptoms of alzheimer type dementia are not correlated wi...
17243915 - The effect of homocysteine reduction by b-vitamin supplementation on inflammatory markers.
11042005 - Adrenocortical function in a new world primate, the marmoset monkey, callithrix jacchus.
17082935 - Significance of hypogonadism in erectile dysfunction.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Nutritional neuroscience     Volume:  9     ISSN:  1028-415X     ISO Abbreviation:  Nutr Neurosci     Publication Date:    2006 Feb-Apr
Date Detail:
Created Date:  2006-08-16     Completed Date:  2006-09-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100892202     Medline TA:  Nutr Neurosci     Country:  England    
Other Details:
Languages:  eng     Pagination:  11-6     Citation Subset:  IM    
Affiliation:
Neurology Division, Department of Neuroscience, "Annunziata" Hospital, Cosenza, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiparkinson Agents / adverse effects*,  therapeutic use
Folic Acid / administration & dosage
Homocysteine / blood*,  genetics,  metabolism
Levodopa / adverse effects*,  therapeutic use
Life Style*
Parkinson Disease / blood*,  drug therapy*
Polymorphism, Genetic
Riboflavin / administration & dosage
Vitamin B 6 / administration & dosage
Chemical
Reg. No./Substance:
0/Antiparkinson Agents; 0/Levodopa; 454-28-4/Homocysteine; 59-30-3/Folic Acid; 8059-24-3/Vitamin B 6; 83-88-5/Riboflavin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relationship between fatty acids and the endocrine and neuroendocrine system.
Next Document:  Expression and activity of methionine cycle genes are altered following folate and vitamin E deficie...